Peter te Boekhorst

Peter te Boekhorst is a researcher in the Department of Hematology at Erasmus MC, Netherlands. He is actively involved in clinical and translational research focusing on hematological disorders, including myelofibrosis, chronic myeloid leukemia (CML), and immune-mediated blood diseases. His work frequently appears in high-impact hematology journals, reflecting ongoing contributions to evidence-based therapeutics and molecular diagnostics.

His research interests span hematology, immunotherapy, circulating tumor cells, cell-free DNA, and molecular monitoring in leukemia. He has contributed significantly to studies on daratumumab use in autoimmune and thrombotic conditions, as well as treatment-free remission in CML using digital PCR.

The recent publications highlight a strong trend toward precision medicine and liquid biopsy applications in hematological malignancies, with emphasis on CD38-targeted therapies, minimal residual disease detection, and clinical outcomes in refractory conditions.

Scientific Contributions:

• Key contributor to clinical studies on daratumumab in autoimmune hematological disorders
• Active participant in multi-center trials on myelofibrosis and CML
• Involved in advancing molecular diagnostics for treatment monitoring

Advising and Grants: While no direct advising or grant information is available, his collaborative publications with senior researchers suggest involvement in funded research programs and mentorship within the Erasmus MC hematology network. He frequently collaborates with experts in molecular hematology and clinical oncology.

Labs and Teams: Peter te Boekhorst is part of the Hematology research team at Erasmus MC, likely integrated into clinical research groups focusing on myeloid malignancies and immunotherapies. His work reflects strong interdisciplinary collaboration across molecular diagnostics, clinical hematology, and translational research.